Researchers have used a bi-specific antibody approach to target the BACE enzyme, which allows transport of the therapeutic antibody across the blood-brain barrier (BBB). The bi-specific antibody reduced the levels of brain Aβ more effectively than a monospecific antibody to BACE1, and this targeting approach could potentially even be applied to treat other neurological diseases. “This is especially welcome, as pharmacological BACE inhibition, long stymied by the challenges presented by its large catalytic site, has not yet survived a phase 1 randomized human clinical trial,” said Dr. Sam Gandy, Professor of Neurology and Psychiatry at Mount Sinai School of Medicine. Learn more